Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

NCT02386501 is registered in ClinicalTrials.gov with Advaxis, Inc. as lead sponsor.

NCT NCT02386501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02386501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Lead sponsor
Advaxis, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2015
Completion date
September 30, 2018
Enrollment
12 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her2 expressing solid tumors